According to our constructed GSRS, the expression of vital ICPs (PD-L1, PD-1, and CTLA4) and TMB was significantly correlated with a risk score, and these indicated that high-risk gliomas were more likely to be sensitive to ICB therapy. The gene discussed is CD274; the disease is central nervous system cancer.